ALLO vs FRT · rev $22.0K vs rev $1.28B
Allogene Therapeutics Inc (ALLO) versus FRT (FRT) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
FRT (FRT) common stock.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
ALLO currently screens at market cap $258.1M. FRT currently screens at market cap $0.
Not investment advice. Open the ALLO and FRT stock pages for the full models.
Not investment advice.